How does tigecycline get metabolized in the body?
Tigecycline is eliminated mostly through non-renal routes, and only a small fraction is cleared by the kidneys. Its handling by the liver is therefore clinically relevant, especially in people with hepatic impairment, because liver function affects drug exposure.
What happens to liver drug metabolism if someone has hepatic impairment?
In patients with liver impairment, tigecycline exposure increases because the liver is less able to clear the drug. That higher exposure can raise the risk of adverse effects, including liver-related laboratory abnormalities. Dose adjustment is commonly considered based on the severity of hepatic impairment.
Does tigecycline “block” liver enzymes or mainly changes exposure?
Available labeling and clinical pharmacology information point to tigecycline causing changes in exposure tied to hepatic function, rather than acting as a classic, strong inhibitor of specific drug-metabolizing enzymes. In practice, the bigger concern is that impaired liver function can raise tigecycline levels, which can then increase toxicity risk.
What liver-related side effects do clinicians watch for?
Patients receiving tigecycline are monitored for abnormal liver tests (for example, elevations in bilirubin, AST, or ALT) and for signs of hepatic dysfunction. These effects tend to be more likely in people who already have compromised liver function or who are receiving other hepatotoxic therapies.
How should doctors manage tigecycline when patients are already on other drugs?
When hepatic metabolism may be altered (for example, in chronic liver disease), clinicians typically review all concurrent medications for overlapping hepatotoxicity and overall clearance burden. Because tigecycline exposure can increase with liver impairment, extra caution is used even if tigecycline itself is not a major enzyme blocker.
Sources
No source material was provided in the prompt to cite for tigecycline’s specific hepatic metabolism pathway, dose-adjustment criteria, or liver-exposure pharmacokinetics.